PSYENCE BIOMEDICAL LTD.
No SEC Form 4 filings for $PBM in the last 30 days.
See all $PBM insider activity →Psyence Biomedical (PBM) shares rose 22.5% after President Trump announced the transfer of the University of Miami’s 1994 Ibogaine Investigational New Drug application to the federal government, aiming to accelerate ibogaine’s development as a medical treatment. The company focuses on psychedelic medicine for mental health conditions.
Eagle Plains Resources (TSXV:EPL, OTCQB:EGPLF) and Pacific Bay Minerals (TSXV:PBM) signed a July 7, 2026 option agreement giving PBM the exclusive right to acquire up to 100% of EPL’s Haskins critical metals project in BC. PBM will pay EPL PBM shares over four years and fund exploration, subject to a 2% NSR.
Psyence BioMed announced the dosing of the first patient in its Phase IIb clinical trial for NPX-5, a nature-derived psilocybin candidate, to treat Adjustment Disorder in cancer patients in palliative care. This marks the initial large-scale clinical evaluation of NPX-5 across an expanded Australian site network, aiming to assess its safety and therapeutic potential. The study expects to generate data on clinical response, safety, tolerability, and treatment durability to inform future development strategies.
Over the past 7 days, alphai's AI scored 1 news story mentioning PBM (PSYENCE BIOMEDICAL LTD.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent PBM coverage spans financial news, market movers and mergers & acquisitions.
The announcement is a direct catalyst for PBM’s ibogaine development narrative, potentially improving access to FDA authorization and accelerating timelines.
PBM’s risk/reward improves if exploration de-risks the Haskins asset, but dilution and capped exploration spend are explicit constraints.
The initiation of a Phase IIb trial for NPX-5 suggests potential future growth for Psyence BioMed, especially if the trial yields positive results. The bullish sentiment indicates investor optimism.
Psyence BioMed announced a major breakthrough in supplying pharmaceutical-grade ibogaine, which could positively influence its stock performance and industry perception.
Psyence BioMed's recent USD 3.5 million investment indicates strong growth prospects and positive investor sentiment, potentially leading to upward price movement.
alphai scores every news story that mentions PBM with an AI model for sentiment and relevance, and aggregates insider trades from PSYENCE BIOMEDICAL LTD.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Psyence Biomedical (PBM) shares rose 22.5% after President Trump announced the transfer of the University of Miami’s 1994 Ibogaine Investigational New Drug application to the federal government, aiming to accelerate ibogaine’s development as a medical treatment. The company focuses on psychedelic medicine for mental health conditions.
3 min readEagle Plains Resources (TSXV:EPL, OTCQB:EGPLF) and Pacific Bay Minerals (TSXV:PBM) signed a July 7, 2026 option agreement giving PBM the exclusive right to acquire up to 100% of EPL’s Haskins critical metals project in BC. PBM will pay EPL PBM shares over four years and fund exploration, subject to a 2% NSR.
4 min readPsyence BioMed announced the dosing of the first patient in its Phase IIb clinical trial for NPX-5, a nature-derived psilocybin candidate, to treat Adjustment Disorder in cancer patients in palliative care. This marks the initial large-scale clinical evaluation of NPX-5 across an expanded Australian site network, aiming to assess its safety and therapeutic potential. The study expects to generate data on clinical response, safety, tolerability, and treatment durability to inform future development strategies.
3 min readNEW YORK, Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Psyence Biomedical Ltd. ( NASDAQ:PBM ) ( "Psyence BioMed" or the "Company" ) , a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced it had established a sustainable ...
3 min readNEW YORK, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Psyence Biomedical Ltd. ( Nasdaq: PBM ) ( "Psyence BioMed" or the "Company" ) , a biopharmaceutical company advancing nature-derived psilocybin and Ibogaine therapies for unmet mental health needs, today announced it has made a USD$3,500,000 ...
3 min read
